Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.50 |
| ▸ | TSHR | P16473 | 4/20 | 0.50 |
| ▸ | TP53 | P04637 | 3/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | PKM | P14618 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 7/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.43 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3639695 | 1.00 | ALDH1A1 (0.50) | ALDH1A1TSHRTP53CYP3A4HIF1A | |
| SCHEMBL11261358 | 0.83 | ALDH1A1 (0.52) | ALDH1A1TSHRTP53CYP3A4HIF1A | |
| SCHEMBL5765504 | 0.83 | SIGMAR1 (0.52) | ALDH1A1TSHRCYP3A4SMN1; SMN2LMNA | |
| SCHEMBL2205094 | 0.81 | PKM (0.51) | ALDH1A1TSHRTP53CYP3A4HIF1A | |
| SCHEMBL10268068 | 0.80 | TLR4 (0.51) | ALDH1A1CYP3A4LMNAMAPTTDP1 | |
| SCHEMBL9737497 | 0.79 | ALDH1A1 (0.61) | ALDH1A1TSHRTP53CYP3A4HIF1A | |
| SCHEMBL7611507 | 0.79 | ALDH1A1 (0.61) | ALDH1A1TSHRTP53CYP3A4HIF1A | |
| SCHEMBL6641309 | 0.79 | ALDH1A1 (0.61) | ALDH1A1TSHRTP53CYP3A4HIF1A | |
| SCHEMBL517975 | 0.79 | ALDH1A1 (0.61) | ALDH1A1TSHRTP53CYP3A4HIF1A | |
| SCHEMBL11420051 | 0.79 | MAPT (0.62) | ALDH1A1TSHRCYP3A4SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2170334-B1 | NMDA RECEPTOR ANTAGONISTS FOR NEUROPROTECTION | UNIV EMORY (US) | 2021-03-17 | — | — | EP | disclosed |
| US-9079852-B2 | NMDA receptor antagonists for neuroprotection | EMORY UNIVERSITY (US) | 2015-07-14 | — | — | US | disclosed |
| US-9079852-B2 | NMDA receptor antagonists for neuroprotection | EMORY UNIVERSITY (US) | 2015-07-14 | — | — | US | disclosed |
| US-20140031363-A1 | NMDA Receptor Antagonists for Neuroprotection | LIOTTA DENNIS C (US) | 2014-01-30 | — | — | US | disclosed |
| US-20140031363-A1 | NMDA Receptor Antagonists for Neuroprotection | LIOTTA DENNIS C (US) | 2014-01-30 | — | — | US | disclosed |
| US-8420680-B2 | NMDA receptor antagonists for neuroprotection | EMORY UNIVERSITY (US) | 2013-04-16 | — | — | US | disclosed |
| US-8420680-B2 | NMDA receptor antagonists for neuroprotection | EMORY UNIVERSITY (US) | 2013-04-16 | — | — | US | disclosed |
| EP-2170334-A1 | NMDA RECEPTOR ANTAGONISTS FOR NEUROPROTECTION | Emory University (US) | 2010-04-07 | — | — | EP | disclosed |
| US-20090253710-A1 | NMDA Receptor Antagonists for Neuroprotection | EMORY UNIVERSITY | 2009-10-08 | — | — | US | disclosed |
| US-20090253710-A1 | NMDA Receptor Antagonists for Neuroprotection | EMORY UNIVERSITY | 2009-10-08 | — | — | US | disclosed |
| US-6060492-A | SIDE EFFECT REDUCTION | ELI LILLY AND COMPANY (US) | 2000-05-09 | — | — | US | disclosed |
| US-5977154-A | OBESITY, DIABETES | ELI LILLY AND COMPANY (US) | 1999-11-02 | — | — | US | disclosed |
| US-5939443-A | ANTIDIABETIC AGENTS AND TREATMENT OF OBESITY | ELI LILLY AND COMPANY (US) | 1999-08-17 | — | — | US | disclosed |
| US-5840738-A | Selective β-3 adrenergic agonists | ELI LILLY AND COMPANY (US) | 1998-11-24 | — | — | US | disclosed |
| US-5808080-A | Selective β3 adrenergic agonists | ELI LILLY AND COMPANY (US) | 1998-09-15 | — | — | US | disclosed |
| US-5786356-A | TREATING TYPE II DIABETES, OBESITY | ELI LILLY AND COMPANY (US) | 1998-07-28 | — | — | US | disclosed |
| WO-1997010825-A1 | SELECTIVE β3 ADRENERGIC AGONISTS | ELI LILLY AND COMPANY (US) | 1997-03-27 | — | — | WO | disclosed |
| EP-0764640-A1 | Selective beta3 adrenergic agonists | ELI LILLY AND COMPANY (US) | 1997-03-26 | — | — | EP | disclosed |
| US-5541204-A | Aryloxypropanolamine β 3 adrenergic agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-07-30 | — | — | US | disclosed |
| EP-0714883-A1 | Aryloxypropanolamine beta 3 adrenergic agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-06-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253710-A1 | NMDA Receptor Antagonists for Neuroprotection | GRIN1, GRIN2C, GRIK1 | ALDH1A1 2664/4885TSHR 1062/4885TP53 4001/4885 |
| US-20140031363-A1 | NMDA Receptor Antagonists for Neuroprotection | GRIN1, GRIN2C, GRIK1 | ALDH1A1 2668/4885TSHR 1080/4885TP53 3922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.